Novel Formulation Concept for Particulate Uptake of Vaccines via the Nasal Associated Lymphoid Tissue

Procedia in Vaccinology

Volumn 4, Issue , 2011, Pages 113-119

  Scherließ, Regina ^a   Trows, Sabrina ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

BSA; Chitosan; Mucosal vaccination; Nasal cast model; Nasal dry powder formulation; Particulate uptake; Vaccine formulation

Indexed keywords

CHITOSAN; VACCINE;

ARTICLE; DRUG FORMULATION; DRY POWDER; HUMAN; INHALATION; LYMPHOID TISSUE; NOSE CAVITY; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM; SPRAY DRYING;

EID: 80053413466     PISSN: None     EISSN: 1877282X     Source Type: Journal    
DOI: 10.1016/j.provac.2011.07.016     Document Type: Article

References (17)

1. Mittal SK, HogenEsch H, Park K, Vaccines and other Immunological Products. In: Swabrick J, editor. Encyclopedia of Pharmaceutical Technology, Informa Healthcare 2007, p. 3908-3926.
2. Wilson-Welder J.H., Torres M.P., Kipper M.J., Mallapragada S.K., Wannemuehler M.J., Narasimhan B. Vaccine Adjuvants: Curent Challenges and Future Approaches. J Pharm Sci 2009, 98:1278-1316.
3. Nochi T., Tagaki H., Yuki Y., Yang L., Masumura T., Mejima M., et al. Rice-based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccination. PNAS 2007, 104:10986-10991.
4. Melnick J.L. Current Status of Poliovirus Infections. Clinical Microbiology Reviews 1996, 9:293-400.
5. Holmgren J, Czerkinsky C, Eriksson K, Mharandi A, Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges, Vaccine 2003; 21, p. S2/89-S82/95.
6. Shahiwala A, Vyas TK, Amiji MM, Nanocarriers for Systemic and Mucosal Vaccine Delivery, Recent Patents on Drug Delivery & Formulation 2007; 1, p. 1-9.
7. Davies S.S. Nasal vaccines. Adv. Drug Delivery Reviews 2001, 51:21-42.
8. Neutra M.R., Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nature Reviews Immunology 2006, 6:148-158.
9. Holmgren J., Czerkinsky C. Mucosal immunity and vaccines. Nature medicine supplement 2005, 11(4):545-553.
10. Gomez-Marquez J, Megally E, Krarup H, Hickman J, Hu J, Shoemaker J, Inhaled Vaccine Delivery by a Novel Nebulizer and Compressor Designed for Use in Developing Countries, Respiratory Drug Delivery 2008.
11. Sievers RE, Cape SP, McAdams DH, Burger JL, Manion JR, Griffin D et al., Inhalation Delivery of Aerosols of Unit-Dose Dry Powder Vaccines vs. Liquid Vaccines, ISAM, 2009.
12. Costantino HR, Illum L, Brandt G, Johnson PH Quay SC, Intranasal delivery: physicochemical and therapeutic aspects, Int J Pharm 2007; 337, p. 1-24.
13. Geeraedts F, Saluja V, ter Veer W, Amorij JP, Frijlink HW, Wilschut J, Hinrichs WLJ, Huckriede A, Preservation of the Immunogenicity of Dry-powder Influenza H5N1 Whole Inactivated Virus Vaccine at Elevated Storage Temperatures, AAPS Journal 2010; 12, p. 215-222.
14. Egen M, Heyder K, Kohler D, Kranz Y, Müller C, Schiewe J, Schönbrodt T, Method development for deposition studies in a nasal cast, Respiratory Drug Delivery 2010.
15. Mosmann T. Rapid Colorimetric Assay for Cellular Growth and Survival: application to Proliferation and Cytotoxicity Tests. Journal of Immunological Methods 1983, 65:55-63.
16. Illum L., Jabbal-Gill L., Hinchcliffe M., Fisher A.N., Davis S.S. Chitosan as a novel nasal delivery system for vaccines. Adv. Drug Delivery Reviews 2001, 51:81-96.
17. De Jesús Valle M.J., Dinis-Oliveira R.J., Carvalho F., Bastos M.L., Sánchez Navarro A. Toxicological evaluation of lactose and chitosan delivered by inhalation. J Biomater Sci Polymer Edn 2008, 19:387-397.